<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04443244</url>
  </required_header>
  <id_info>
    <org_study_id>HG-BOTBMH-PII-01</org_study_id>
    <nct_id>NCT04443244</nct_id>
  </id_info>
  <brief_title>Evaluate the Safety and Efficacy of Botulax® in Subjects With Benign Masseteric Hypertrophy</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Multi-center Phase Ⅱ Optimal Dose-finding Study to Evaluate the Safety and Efficacy of Botulax® in Subjects With Benign Masseteric Hypertrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hugel</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hugel</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is A Randomized, Double-blind, Placebo-controlled, Multi-center Phase II Optimal
      Dose-finding Study to Evaluate the Safety and Efficacy of Botulax® in Subjects with Benign
      Masseteric Hypertrophy
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Randomized, Double-blind, Placebo-controlled, Multi-center Phase Ⅱ Optimal Dose-finding
      Study to Evaluate the Safety and Efficacy of Botulax® in Subjects with Benign Masseteric
      Hypertrophy
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 27, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Amount of change from baseline in masseter muscle thickness during maximum clenching</measure>
    <time_frame>Baseline to week 12</time_frame>
    <description>Amount of change from baseline in masseter muscle thickness during maximum clenching by Ultrasonography</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Amount of change from baseline in masseter muscle thickness during maximum clenching</measure>
    <time_frame>Baseline to week 4, 8, 16</time_frame>
    <description>Amount of change from baseline in masseter muscle thickness during maximum clenching by Ultrasonography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of change from baseline in masseter muscle thickness during maximum clenching</measure>
    <time_frame>Baseline to week 4, 8, 12, 16</time_frame>
    <description>Rate of change from baseline in masseter muscle thickness during maximum clenching by Ultrasonography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of change from baseline in masseter muscle thickness during resting</measure>
    <time_frame>Baseline to week 4, 8, 12, 16</time_frame>
    <description>Amount of change from baseline in masseter muscle thickness during resting by Ultrasonography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of change from baseline in masseter muscle thickness during resting</measure>
    <time_frame>Baseline to week 4, 8, 12, 16</time_frame>
    <description>Rate of change from baseline in masseter muscle thickness during resting by Ultrasonography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount and rate of change from baseline in lower face volume during maximum clenching</measure>
    <time_frame>Baseline to week 4, 8, 12, 16</time_frame>
    <description>Amount and rate of change from baseline in lower face volume during maximum clenching by 3D imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall improvement of Investigator</measure>
    <time_frame>Baseline to week 4, 8, 12, 16</time_frame>
    <description>Overall improvement of Investigator by assessment scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall satisfaction of subject</measure>
    <time_frame>Baseline to week 4, 8, 12, 16</time_frame>
    <description>Subject satisfaction assessment using a scale ranging from Extremely dissatisfied to Extremely satisfied by questionnaire</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Benign Masseteric Hypertrophy</condition>
  <arm_group>
    <arm_group_label>Botulinum Toxin Type A(Botulax®) 24Units</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Botulinum Toxin Type A (Botulax®) 24Units total dose administered intramuscularly to the bilateral masseter muscles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Botulinum Toxin Type A(Botulax®) 48Units</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Botulinum Toxin Type A (Botulax®) 48Units total dose administered intramuscularly to the bilateral masseter muscles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Botulinum Toxin Type A(Botulax®) 72Units</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Botulinum Toxin Type A (Botulax®) 72Units total dose administered intramuscularly to the bilateral masseter muscles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Botulinum Toxin Type A(Botulax®) 96Units</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Botulinum Toxin Type A (Botulax®) 96Units total dose administered intramuscularly to the bilateral masseter muscles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo(Normal Saline)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo(Normal saline) administered intramuscularly to the bilateral masseter muscles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Botulinum Toxin Type A Injection (Botulax®) 24Units</intervention_name>
    <description>Experimental: Botulax® 24Units</description>
    <arm_group_label>Botulinum Toxin Type A(Botulax®) 24Units</arm_group_label>
    <other_name>Botulax®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Botulinum Toxin Type A Injection (Botulax®) 48Units</intervention_name>
    <description>Experimental: Botulax® 48Units</description>
    <arm_group_label>Botulinum Toxin Type A(Botulax®) 48Units</arm_group_label>
    <other_name>Botulax®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Botulinum Toxin Type A Injection (Botulax®) 72Units</intervention_name>
    <description>Experimental: Botulax® 72Units</description>
    <arm_group_label>Botulinum Toxin Type A(Botulax®) 72Units</arm_group_label>
    <other_name>Botulax®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Botulinum Toxin Type A Injection (Botulax®) 96Units</intervention_name>
    <description>Experimental: Botulax® 96Units</description>
    <arm_group_label>Botulinum Toxin Type A(Botulax®) 96Units</arm_group_label>
    <other_name>Botulax®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Normal Saline</intervention_name>
    <description>Placebo Comparator: Normal Saline</description>
    <arm_group_label>Placebo(Normal Saline)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male and Female adults aged 19 or older.

          2. Sighting, facilitation measurement are judged by the investigator to be the ratio of
             Benign Masseteric Hypertrophy.

          3. Subject who understand and willing to perform with the procedures and visiting
             schedules of clinical trial.

          4. Subject who voluntarily agree to participate in this clinical trial.

        Exclusion Criteria:

          1. Subject who is clinically significant facial asymmetry in visual measurement by the
             investigator.

          2. Fertile women and men who have plans to conceive during pregnancy, breastfeeding and
             clinical trials or who do not agree to appropriate contraception.

          3. Subject who is deemed unable to participate in a clinical trial under the judgement of
             a Investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jin-Hong Park</last_name>
    <phone>82-2-6966-1651</phone>
    <email>jhpark@hugel.co.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hugel</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jin-Hong Park</last_name>
      <phone>82-2-6966-1651</phone>
      <email>jhpark@hugel.co.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 12, 2020</study_first_submitted>
  <study_first_submitted_qc>June 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 23, 2020</study_first_posted>
  <last_update_submitted>June 22, 2020</last_update_submitted>
  <last_update_submitted_qc>June 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertrophy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

